Revvity Signals - Drug Discovery

News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development

Thursday, August 25, 2022

GNS a leading company in the field of biopharmaceutical drug discovery and development using Digital Twins and Causal AI biosimulation technology has announced a collaboration with Servier a global pharmaceutical group to advance efforts in Multiple...

LumaBridge and Parker Institute for Cancer Immunotherapy Announce Strategic Alliance to Streamline Immunotherapy Development

Thursday, August 25, 2022

LumaBridge formerly known as Cancer Insight a clinical research organization CRO dedicated to discovering developing and testing emerging biotechnologies related to cancer therapies and the Parker Institute for Cancer Immunotherapy PICI the largest n...

Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases

Wednesday, August 24, 2022

Roche has unveiled the Digital LightCycler System their first digital polymerase chain reaction PCR system This advanced system is specifically designed to detect diseases and accurately quantify minuscule amounts of specific DNA and RNA targets that...

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

Wednesday, August 24, 2022

Pfizer Inc and BioNTech SE announced updated efficacy results from a Phase trial evaluating a three g dose series of the PfizerBioNTech COVID Vaccine

Translational Research Describes an Epigenetic Approach for Regulating Fear-Memory

Tuesday, August 23, 2022

EpiVario Inc an emerging biotech company dedicated to developing innovative therapeutics for memoryrelated psychiatric disorders has announced significant preclinical research findings that have the potential to lead to a treatment approach for PostT...

Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT

Tuesday, August 23, 2022

Vaderis Therapeutics AG a clinical stage biotechnology company specializing in treatments for rare diseases associated with vascular malformations has emerged from stealth mode and commenced its INSIGHT proofofconcept clinical trial This trial focuse...

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Friday, August 19, 2022

Jazz Pharmaceuticals plc announced it has initiated a new Phase trial to investigate the efficacy and safety of Epidiolex cannabidiol known as Epidyolex in Europe in children and adolescents with Epilepsy with MyoclonicAtonic Seizures EMAS The rando...

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain

Friday, August 19, 2022

Grnenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin RTX RTX is a highly potent Transient Receptor Potential Vanilloid TRPV agonist with a wellvalidated mechanism of...

RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections

Thursday, August 18, 2022

RedHill Biopharma Ltd a specialty biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to RHB for the treatment of nontuberculous mycobacteria NTM disease following a positive opinion recommendati...

Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

Thursday, August 18, 2022

Aytu BioPharma Inc a pharmaceutical company focused on developing and commercializing novel therapeutics today announced that the US Patent and Trademark Office has issued a new patent No the patent for AREnzastaurin This patent titled Targeted Epi...